We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: Diatron has been present at MEDICA for the past 15 years at the same booth location (Photo courtesy of Diatron)
Image: Diatron has been present at MEDICA for the past 15 years at the same booth location (Photo courtesy of Diatron)

Diatron (Budapest, Hungary) is exhibiting its advanced hematology analyzers and clinical chemistry analyzers, along with associated reagents at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Diatron is exhibiting the KleeYa open, flexible CLIA platform which provides a unique approach to the use of different bead-based CLIA technologies, offering superior assay performance and providing ease of use with cost containment. Diatron’s KleeYa, a highly flexible, fast and sensitive random access CLIA platform for immunoassay menu, handles tests from various providers and is able to combine a wide variety of assay designs.

Also on display at the Diatron booth at MEDICA is the company’s new P780 clinical chemistry analyzer alongside the Aquila 3-part differential hematology analyzer. The Diatron Aquila is an innovative and revolutionary hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. The Diatron Aquila can be used to perform complete CBC with human blood, collected in either standard EDTA collection tubes (Vacutainer type) or with micro sampling tubes. It delivers accurate results with regular and micro-sampling collection tubes with only 20 μl blood required and results in less than one minute. The QC menu offers the user the opportunity to use secondary QC limits for all parameters providing the extended QC option. The Diatron Aquila featuring the company’s latest technology offers an optimal testing solution for both experienced and inexperienced users and practices that require a high quality hematology analyzer.

Related Links:
Diatron 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.